Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests

Psychoneuroendocrinology

Volumn 69, Issue , 2016, Pages 161-171

  Menke, Andreas ^a,b   Arloth, Janine ^b   Best, Johanna ^b   Namendorf, Christian ^b   Gerlach, Tamara ^b   Czamara, Darina ^b   Lucae, Susanne ^b   Dunlop, Boadie W ^c   Crowe, Tanja Mletzko ^c   Garlow, Steven J ^c   Nemeroff, Charles B ^d   Ritchie, James C ^e   Craighead, W Edward ^c   Mayberg, Helen S ^c   Rex Haffner, Monika ^b   Binder, Elisabeth B ^b,c   Uhr, Manfred ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Dex CRH test; Dexamethasone; DST; Gene expression; Glucocorticoid receptor; Major depression

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; MESSENGER RNA; ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; COGNITIVE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DEXAMETHASONE CORTICOTROPIN RELEASING HORMONE TEST; DEXAMETHASONE SUPPRESSION TEST; DRUG BLOOD LEVEL; ENDOCRINE FUNCTION TEST; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MASS; MASS SPECTROMETRY; PRIORITY JOURNAL; TIME; TREATMENT RESPONSE; BLOOD; DEPRESSION; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DEXAMETHASONE; FEMALE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID; TIME FACTORS;

EID: 84963756190     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.04.003     Document Type: Article

References (52)

1. Appelhof B.C., Huyser J., Verweij M., Brouwer J.P., van Dyck R., Fliers E., Hoogendijk W.J., Tijssen J.G., Wiersinga W.M., Schene A.H. Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol. Psychiatry 2006, 59:696-701.
2. Arana G.W., Baldessarini R.J., Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch. Gen. Psychiatry 1985, 42:1193-1204.
3. Arloth J., Bogdan R., Weber P., Frishman G., Menke A., Wagner K.V., Balsevich G., Schmidt M.V., Karbalai N., Czamara D., Altmann A., Trumbach D., Wurst W., Mehta D., Uhr M., Klengel T., Erhardt A., Carey C.E., Conley E.D., Ruepp A., Muller-Myhsok B., Hariri A.R., Binder E.B. Major depressive disorder working group of the psychiatric genomics consortium PGC genetic differences in the immediate transcriptome response to stress predict risk-related brain function and psychiatric disorders. Neuron 2015, 86:1189-1202.
4. Bardeleben U., Holsboer F. Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression. J. Neuroendocrinol. 1989, 1:485-488.
5. Belvederi Murri M., Pariante C., Mondelli V., Masotti M., Atti A.R., Mellacqua Z., Antonioli M., Ghio L., Menchetti M., Zanetidou S., Innamorati M., Amore M. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology 2014, 41:46-62.
6. Carpenter L.L., Ross N.S., Tyrka A.R., Anderson G.M., Kelly M., Price L.H. Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology 2009, 34:1208-1213.
7. Carroll B.J., Martin F.I., Davies B. Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. Br. Med. J. 1968, 3:285-287.
8. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N.M., Kronfol Z., Lohr N., Steiner M., de Vigne J.P., Young E. A specific laboratory test for the diagnosis of melancholia standardization, validation, and clinical utility. Arch. Gen. Psychiatry 1981, 38:15-22.
9. Coryell W., Schlesser M. The dexamethasone suppression test and suicide prediction. Am. J. Psychiatry 2001, 158:748-753.
10. Czock D., Keller F., Rasche F.M., Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 2005, 44:61-98.
11. Dunlop B.W., Binder E.B., Cubells J.F., Goodman M.M., Kelley M.E., Kinkead B., Kutner M., Nemeroff C.B., Newport D.J., Owens M.J., Pace T.W., Ritchie J.C., Rivera V.A., Westen D., Craighead W.E., Mayberg H.S. Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials 2012, 13:106.
12. Gentile D.M., Tomlinson E.S., Maggs J.L., Park B.K., Back D.J. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J. Pharmacol. Exp. Ther. 1996, 277:105-112.
13. Gervasoni N., Bertschy G., Osiek C., Perret G., Denis R., Golaz J., Rossier M.F., Bondolfi G., Aubry J.M. Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode. J. Psychiatr. Res. 2004, 38:553-557.
14. Guthrie S.K., Vartanian L., Grunhaus L., Hariharan M., Pande A., Haskett R.F. A longitudinal evaluation of dexamethasone and cortisol plasma concentrations in the dexamethasone suppression test before and during treatment with antidepressant drugs. Acta Psychiatr. Scand. 1990, 82:427-432.
15. Heuser I., Yassouridis A., Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J. Psychiatr. Res. 1994, 28:341-356.
16. Hinchliffe E., Carter S., Owen L.J., Keevil B.G. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 913-914:19-23.
17. Holsboer F., Bender W., Benkert O., Klein H.E., Schmauss M. Diagnostic value of dexamethasone suppression test in depression. Lancet 1980, 2:706.
18. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
19. Holsboer F. How can we realize the promise of personalized antidepressant medicines?. Nat. Rev. Neurosci. 2008, 9:638-646.
20. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., Kunzel H.E., Pfennig A., Uhr M., Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker?. Biol. Psychiatry 2007, 62:47-54.
21. Ising M., Lucae S., Binder E.B., Bettecken T., Uhr M., Ripke S., Kohli M.A., Hennings J.M., Horstmann S., Kloiber S., Menke A., Bondy B., Rupprecht R., Domschke K., Baune B.T., Arolt V., Rush A.J., Holsboer F., Muller-Myhsok B. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 2009, 66:966-975.
22. Jarcho M.R., Slavich G.M., Tylova-Stein H., Wolkowitz O.M., Burke H.M. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol. Psychol. 2013, 93:150-158.
23. Johnson G.F., Hunt G.E., Caterson I. Plasma dexamethasone and the dexamethasone suppression test. Initial and follow-up tests in depressed patients. J. Affect. Disord. 1988, 15:93-100.
24. Kaestner F., Hettich M., Peters M., Sibrowski W., Hetzel G., Ponath G., Arolt V., Cassens U., Rothermundt M. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 2005, 87:305-311.
25. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
26. Kunugi H., Urushibara T., Nanko S. Combined DEX/CRH test among Japanese patients with major depression. J. Psychiatr. Res. 2004, 38:123-128.
27. Kunugi H., Ida I., Owashi T., Kimura M., Inoue Y., Nakagawa S., Yabana T., Urushibara T., Kanai R., Aihara M., Yuuki N., Otsubo T., Oshima A., Kudo K., Inoue T., Kitaichi Y., Shirakawa O., Isogawa K., Nagayama H., Kamijima K., Nanko S., Kanba S., Higuchi T., Mikuni M. Assessment of the Dexamethasone/CRH Test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology 2006, 31:212-220.
28. Kunzel H.E., Binder E.B., Nickel T., Ising M., Fuchs B., Majer M., Pfennig A., Ernst G., Kern N., Schmid D.A., Uhr M., Holsboer F., Modell S. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 2003, 28:2169-2178.
29. Menke A., Arloth J., Putz B., Weber P., Klengel T., Mehta D., Gonik M., Rex-Haffner M., Rubel J., Uhr M., Lucae S., Deussing J.M., Muller-Myhsok B., Holsboer F., Binder E.B. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 2012, 37:1455-1464.
30. Menke A., Arloth J., Gerber M., Rex-Haffner M., Uhr M., Holsboer F., Binder E.B., Holsboer-Trachsler E., Beck J. Dexamethasone stimulated gene expression in peripheral blood indicates glucocorticoid-receptor hypersensitivity in job-related exhaustion. Psychoneuroendocrinology 2014, 44:35-46.
31. Modell S., Yassouridis A., Huber J., Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 1997, 65:216-222.
32. Muller M.B., Keck M.E., Binder E.B., Kresse A.E., Hagemeyer T.P., Landgraf R., Holsboer F., Uhr M. ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 2003, 28:1991-1999.
33. Nelson J.C., Davis J.M. DST studies in psychotic depression: a meta-analysis. Am. J. Psychiatry 1997, 154:1497-1503.
34. Nierenberg A.A., Feinstein A.R. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA 1988, 259:1699-1702.
35. O'Sullivan B.T., Hunt G.E., Johnson G.F., Caterson I.D. The plasma dexamethasone window: evidence supporting its usefulness to validate dexamethasone suppression test results. Biol. Psychiatry 1989, 25:739-754.
36. O'Sullivan B.T., Cutler D.J., Hunt G.E., Walters C., Johnson G.F., Caterson I.D. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol. Psychiatry 1997, 41:574-584.
37. Oshima A., Yamashita S., Owashi T., Murata T., Tadokoro C., Miyaoka H., Kamijima K., Higuchi T. The differential ACTH responses to combined dexamethasone/CRH administration in major depressive and dysthymic disorders. J. Psychiatr. Res. 2000, 34:325-328.
38. Owashi T., Otsubo T., Oshima A., Nakagome K., Higuchi T., Kamijima K. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression. Psychoneuroendocrinology 2008, 33:152-161.
39. Pfennig A., Kunzel H.E., Kern N., Ising M., Majer M., Fuchs B., Ernst G., Holsboer F., Binder E.B. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol. Psychiatry 2005, 57:336-342.
40. Poland R.E., Rubin R.T., Lesser I.M. Serum dexamethasone concentrations in endogenous depressives before, during, and after treatment: preliminary observations. Biol. Psychiatry 1988, 23:705-710.
41. Pruessner J.C., Kirschbaum C., Meinlschmid G., Hellhammer D.H. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003, 28:916-931.
42. Ritchie J.C., Belkin B.M., Krishnan K.R., Nemeroff C.B., Carroll B.J. Plasma dexamethasone concentrations and the dexamethasone suppression test. Biol. Psychiatry 1990, 27:159-173.
43. Rydmark I., Wahlberg K., Ghatan P.H., Modell S., Nygren A., Ingvar M., Asberg M., Heilig M. Neuroendocrine, cognitive and structural imaging characteristics of women on longterm sickleave with job stress-induced depression. Biol. Psychiatry 2006, 60:867-873.
44. Spina E., Trifiro G., Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012, 26:39-67.
45. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 2011, 73:114-126.
46. Uhr M., Holsboer F., Muller M.B. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J. Neuroendocrinol. 2002, 14:753-759.
47. Ustun T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 2004, 184:386-392.
48. Xiang L., Marshall G.D. Immunomodulatory effects of dexamethasone on gene expression of cytokine and stress hormone receptors in peripheral blood mononuclear cells. Int. Immunopharmacol. 2013, 17:556-560.
49. Young E., Korszun A. Sex, trauma, stress hormones and depression. Mol. Psychiatry 2010, 15:23-28.
50. Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013, 138:103-141.
51. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J. Psychiatr. Res. 2001, 35:83-94.
52. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6:463-475.